QT lengthening and life-threatening arrhythmias associated with fexofenadine
1999; Elsevier BV; Volume: 353; Issue: 9157 Linguagem: Inglês
10.1016/s0140-6736(99)01009-0
ISSN1474-547X
AutoresYM Pinto, IC van Gelder, Marten Heeringa, Hjgm Crijns,
Tópico(s)Pesticide Residue Analysis and Safety
ResumoFor clinicians treating patients with suspected or known QTc prolongation and ventricular arrhythmias, it is important to be aware of rare but life-threatening arrhythmogenic properties of some antihistamines. Fexofenadine, a histamine H1-receptor antagonist used for the treatment of seasonal allergic rhinitis, was approved by the FDA in December, 1996, with its main advantage being its proposed lack of effect on QTc time. Fexofenadine is the primary active derivative of terfenadine. Terfenadine was withdrawn because of its association with cardiac arrhythmias mainly in conjunction with macrolide antibiotics and antifungal medication. These adverse effects of terfenadine were known for several years but it was only withdrawn after the approval of fexofenadine, which was reported not to cause cardiotoxic reactions. 1 Markham A Wagstaff AJ Fexofenadine. Drugs. 1998; 55: 269-274 Crossref PubMed Scopus (174) Google Scholar
Referência(s)